LYEL Covered Call Strategy

LYEL (Lyell Immunopharma, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

LYEL (Lyell Immunopharma, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $448.9M, a beta of -0.06 versus the broader market, a 52-week range of 7.65-45, average daily share volume of 95K, a public-listing history dating back to 2021, approximately 300 full-time employees. These structural characteristics shape how LYEL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of -0.06 indicates LYEL has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a covered call on LYEL?

A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.

Current LYEL snapshot

As of May 15, 2026, spot at $18.01, ATM IV 151.00%, IV rank 30.79%, expected move 43.29%. The covered call on LYEL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this covered call structure on LYEL specifically: LYEL IV at 151.00% is mid-range versus its 1-year history, so the credit collected on a LYEL covered call sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 43.29% (roughly $7.80 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LYEL expiries trade a higher absolute premium for lower per-day decay. Position sizing on LYEL should anchor to the underlying notional of $18.01 per share and to the trader's directional view on LYEL stock.

LYEL covered call setup

The LYEL covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LYEL near $18.01, the first option leg uses a $19.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LYEL chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LYEL shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 100 sharesStock$18.01long
Sell 1Call$19.00$3.02

LYEL covered call risk and reward

Net Premium / Debit
-$1,499.00
Max Profit (per contract)
$401.00
Max Loss (per contract)
-$1,498.00
Breakeven(s)
$14.99
Risk / Reward Ratio
0.268

Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.

LYEL covered call payoff curve

Modeled P&L at expiration across a range of underlying prices for the covered call on LYEL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price% From SpotP&L at Expiration
$0.01-99.9%-$1,498.00
$3.99-77.8%-$1,099.90
$7.97-55.7%-$701.80
$11.95-33.6%-$303.70
$15.93-11.5%+$94.40
$19.92+10.6%+$401.00
$23.90+32.7%+$401.00
$27.88+54.8%+$401.00
$31.86+76.9%+$401.00
$35.84+99.0%+$401.00

When traders use covered call on LYEL

Covered calls on LYEL are an income strategy run on existing LYEL stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.

LYEL thesis for this covered call

The market-implied 1-standard-deviation range for LYEL extends from approximately $10.21 on the downside to $25.81 on the upside. A LYEL covered call collects premium on an existing long LYEL position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether LYEL will breach that level within the expiration window. Current LYEL IV rank near 30.79% is mid-range against its 1-year distribution, so the IV signal is neutral; the covered call thesis on LYEL should anchor more to the directional view and the expected-move geometry. As a Healthcare name, LYEL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LYEL-specific events.

LYEL covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LYEL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LYEL alongside the broader basket even when LYEL-specific fundamentals are unchanged. Short-premium structures like a covered call on LYEL carry tail risk when realized volatility exceeds the implied move; review historical LYEL earnings reactions and macro stress periods before sizing. Always rebuild the position from current LYEL chain quotes before placing a trade.

Frequently asked questions

What is a covered call on LYEL?
A covered call on LYEL is the covered call strategy applied to LYEL (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With LYEL stock trading near $18.01, the strikes shown on this page are snapped to the nearest listed LYEL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are LYEL covered call max profit and max loss calculated?
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the LYEL covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 151.00%), the computed maximum profit is $401.00 per contract and the computed maximum loss is -$1,498.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a LYEL covered call?
The breakeven for the LYEL covered call priced on this page is roughly $14.99 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LYEL market-implied 1-standard-deviation expected move is approximately 43.29%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a covered call on LYEL?
Covered calls on LYEL are an income strategy run on existing LYEL stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
How does current LYEL implied volatility affect this covered call?
LYEL ATM IV is at 151.00% with IV rank near 30.79%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related LYEL analysis